Literature DB >> 30322320

Real world experience with "generic" pomalidomide in relapsed refractory multiple myeloma.

Aditya Jandial1, Kundan Mishra1, Deepesh Lad1, Gaurav Prakash1, Alka Khadwal1, Pankaj Malhotra1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30322320     DOI: 10.1080/10428194.2018.1508675

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


× No keyword cloud information.
  2 in total

1.  Poor Mobilisation After Daratumumab Based Combination Chemotherapy in Patients of Newly Diagnosed Multiple Myeloma.

Authors:  Kundan Mishra; Aditya Jandial; Rajeev Sandal; Deepesh Lad; Gaurav Prakash; Alka Khadwal; Pankaj Malhotra
Journal:  Indian J Hematol Blood Transfus       Date:  2019-05-10       Impact factor: 0.900

2.  Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients.

Authors:  Marina Silvia Parisi; Salvatore Leotta; Alessandra Romano; Vittorio Del Fabro; Enrica Antonia Martino; Valeria Calafiore; Rachele Giubbolini; Uros Markovic; Valerio Leotta; Mary Ann Di Giorgio; Daniele Tibullo; Francesco Di Raimondo; Concetta Conticello
Journal:  J Clin Med       Date:  2019-10-16       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.